2597-28-6

Usage

Uses

Used in Pharmaceutical Industry:
(1,2-DiMethyl-1H-indol-3-yl)-acetic acid is used as a potential medicinal compound for its anti-inflammatory and antioxidant effects. It is being studied for its potential use as a drug targeting the central nervous system.
Used in Cancer Treatment:
(1,2-DiMethyl-1H-indol-3-yl)-acetic acid is used as a potential cancer treatment agent due to its ability to inhibit cell proliferation and induce apoptosis in cancer cells.

Upstream product

• 1912-43-2 2-methyl-3-indoleacetic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 72228-43-4 2-(N-Methyl-2-methyl-3-indolyl)propionic Acid 

Relevant academic research and scientific papers

CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6)

The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein-like peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds or pharmaceutical compositions.

Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity

Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity-based probe, could be used to pull down active endogenous KLK6.

Synthesis of functionalized pyrroloindolines: Via a visible-light-induced radical cascade reaction: Rapid synthesis of (±)-flustraminol B

The development of visible-light-induced synthesis of functionalized pyrroloindolines via a radical cascade reaction is reported. The reaction shows a broad substrate scope and highlights the mild nature of the reaction conditions. A range of substitutions on indole aromatic rings and N-centers is well tolerated, including a free allylic alcohol. Relying on the strategy, a rapid synthesis of (±)-flustraminol B was achieved.